Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 1,112 | 3,411 | 3,604 | 4,746 | 2,395 |
| Gross Profit | 1,112 | 3,411 | 3,604 | 4,746 | 2,395 |
| Operating Expenses | 22,411 | 27,741 | 19,850 | 20,996 | 25,779 |
| Operating Income | -21,299 | -24,330 | -16,246 | -16,250 | -23,384 |
| Interest Expense | 27 | 29 | 713 | 1,471 | 1,440 |
| Other Income | 398 | 298 | 64,700 | -99,366 | 226 |
| Pre-tax Income | -20,928 | -24,061 | 47,741 | -117,087 | -24,598 |
| Net Income Continuous | -20,928 | -24,061 | 47,741 | -117,087 | -24,598 |
| Net Income | $-20,928 | $-24,061 | $47,741 | $-117,087 | $-24,598 |
| EPS Basic Total Ops | -0.09 | -0.10 | 0.63 | -0.93 | -0.38 |
| EPS Basic Continuous Ops | -0.09 | -0.10 | 0.63 | -0.93 | -0.38 |
| EPS Diluted Total Ops | -0.09 | -0.10 | 0.63 | -0.93 | -0.38 |
| EPS Diluted Continuous Ops | -0.09 | -0.10 | 0.63 | -0.93 | -0.38 |
| EPS Diluted Before Non-Recurring Items | -0.09 | -0.10 | 0.35 | N/A | N/A |
| EBITDA(a) | $-20,977 | $-24,005 | $-15,880 | $-15,919 | $-23,041 |